Partners Capital Investment Group LLP Purchases New Shares in United Therapeutics Corporation $UTHR

Partners Capital Investment Group LLP acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 3,120 shares of the biotechnology company’s stock, valued at approximately $1,691,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Torren Management LLC acquired a new stake in shares of United Therapeutics during the fourth quarter valued at about $26,000. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics during the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.0%

Shares of UTHR opened at $512.88 on Tuesday. The firm has a market cap of $22.00 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 1.74 and a beta of 0.59. The stock has a 50 day moving average of $532.35 and a 200-day moving average of $538.04. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $6.41 EPS. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,311,581.28. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,185,323.93. This trade represents a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 434,075 shares of company stock valued at $233,942,595. 8.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of several analyst reports. Royal Bank Of Canada dropped their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Finally, Bank of America decreased their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.